deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 3-arm NCT01002235

Gene Therapy for Painful Diabetic Neuropathy

A Phase I/II, Open Label, Dose-Escalation Study to Assess the Safety and Tolerability of Engensis (VM202) in Patients With Painful Diabetic Peripheral Neuropathy

Sponsor: Helixmith Co., Ltd.

Conditions Painful Diabetic Peripheral Neuropathy
Interventions VM202
Updated 14 times since 2017 Last updated: Sep 23, 2025 Started: Feb 28, 2010 Primary completion: Apr 30, 2011 Completion: Apr 30, 2012
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Painful Diabetic Peripheral Neuropathy, this trial is completed. The trial is conducted by Helixmith Co., Ltd. and has accumulated 14 data snapshots since 2010. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Feb 2018 · 12 months · monthly snapshot~Feb 2018 – ~Jun 2018 · 4 months · monthly snapshot~Jun 2018 – ~Jun 2019 · 12 months · monthly snapshot~Jun 2019 – ~Sep 2019 · 3 months · monthly snapshot~Sep 2019 – ~Nov 2019 · 2 months · monthly snapshot~Nov 2019 – ~Jan 2021 · 14 months · monthly snapshot~Jan 2021 – ~Apr 2022 · 15 months · monthly snapshot~Apr 2022 – ~Jul 2024 · 27 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Jul 2025 · 10 months · monthly snapshot~Jul 2025 – ~Aug 2025 · 31 days · monthly snapshot~Aug 2025 – ~Nov 2025 · 3 months · monthly snapshot~Nov 2025 – present · 8 months · monthly snapshot

Change History

14 versions recorded

  1. Nov 2025 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Aug 2025 — Nov 2025 [monthly]

    Completed PHASE1/PHASE2

  3. Jul 2025 — Aug 2025 [monthly]

    Completed PHASE1/PHASE2

  4. Sep 2024 — Jul 2025 [monthly]

    Completed PHASE1/PHASE2

  5. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

▶ Show 9 earlier versions

  1. Apr 2022 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

  2. Jan 2021 — Apr 2022 [monthly]

    Completed PHASE1_PHASE2

  3. Nov 2019 — Jan 2021 [monthly]

    Completed PHASE1_PHASE2

  4. Sep 2019 — Nov 2019 [monthly]

    Completed PHASE1_PHASE2

  5. Jun 2019 — Sep 2019 [monthly]

    Completed PHASE1_PHASE2

  6. Jun 2018 — Jun 2019 [monthly]

    Completed PHASE1_PHASE2

  7. Feb 2018 — Jun 2018 [monthly]

    Completed PHASE1_PHASE2

  8. Feb 2017 — Feb 2018 [monthly]

    Completed PHASE1_PHASE2

  9. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE1_PHASE2

    First recorded

Feb 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Helixmith Co., Ltd.
Data source: Helixmith Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations